Drug Discovery Informatics Market Research Report Information By Product (Discovery Informatics, Development Informatics), Mode (In-House Informatics and Outsourced Informatics), Service (Sequencing and Target Data Analysis, Docking, Molecular Modeling, Clinical Trial Data Management and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Drug Discovery Informatics Market Overview

Drug Discovery Informatics Market Size was projected at USD 3.43 Billion in 2023. The Global Drug Discovery Informatics market industry is projected to grow from USD 3.800 Billion in 2024 to USD 7.8 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.40% during the projected timeframe (2024 - 2032). There is a growing need to keep medication discovery and development expenses under control, and an increase in expenditure on research and development are the key market drivers contributing to market growth and expansion. 

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

For example, in February 2023, Insilico Medicine launched its Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Centre in Abu Dhabi, the largest AI-driven biotech research center in the region.

In February 2023, Evotec SE extended its integrated multi-target drug discovery agreement with Related Sciences, a data-driven biotechnology creation company. This will enable them to leverage their lead role across the whole R&D chain through 2030 on their joint portfolio of drug development candidates.

An instance is that in April 2022, Iktos, which specializes in Artificial Intelligence (AI) for new drug design and Teijin Pharma Limited—the core company today of Teijin Group’s healthcare business who, offers comprehensive healthcare services to improve quality of life—announced strategic collaboration agreement regarding Artificial Intelligence with reference to small molecules’ discovery.

For example, Cyclica announced Perturba Therapeutics during February 2022—a University of Toronto spin-out specializing in AI-powered oncology drug design; Perturba aims to tackle this by plugging Cyclica’s complete AI-augmented proteome-wide drug design platform into two first-in-class live cell-based assays from Stagljar Lab.”

Similarly, in January 2022, Fosun Pharma, a China-based healthcare group and Insilico Medicine teamed up towards discovery and development of drugs targeting different targets globally using artificial intelligence (AI).

For example, PostEra expanded Pfizer’s existing strategic partnership in January 2022, with a biotech firm specialized with machine learning for pre-clinical drug discovery. The enlarged multi-target research program has created an AI Lab where multiple drug discovery programs are being advanced jointly by PostEra and Pfizer initially focusing on oncology as well as COVID-19 antiviral therapeutics. In addition, Pfizer's data builds upon novel machine learning for medicinal chemistry at the AI Lab facilitated by PostEra’s generative chemistry & synthesis-aware design.

Atomwise, a leading player in AI-driven small molecule drug discovery, made an announcement in December 2020 that expanded its portfolio through joint ventures with A2i Therapeutics and FutuRx.

For example, in March 2020, Charles River Laboratories International Inc. collaboratively worked with Deciphex. This collaboration involved the use of Deciphex’s Patholytix Preclinical platform designed to improve pathologists’ output and accelerate the delivery of findings to customers.

Drug Discovery Informatics Market Trends

• The growing chronic illness burden is driving the market growth

The rising chronic illness burden drives Market CAGR for Drug Discovery Informatics. Rising R&D spending, increased funding for studies, especially in rare diseases, and increased use of bioinformatics in the development of drugs are driving market growth. The cost of discovering drugs, studying, and developing them is increasing dramatically. Most medication clinical trials are funded by pharmaceutical companies, which spend hundreds of millions of USD on drug development. Other factors propelling the drug discovery informatics business include pharmaceutical corporations' increasing involvement in a drug study and a pressing need to reduce the development and discovery of drugs expenses. Given that technologies based on data remain in their early stages, they are expected to expand rapidly. In addition, certain benefits offered by drug delivery informatics remedies, including enhanced drug discovery procedure storing and extraction, knowledge organization, and immediate information that may be utilized in making decisions, are projected to propel the worldwide drug discovery informatics marketplace throughout forecasting.

Additionally, it assists clients in making key decisions regarding optimizing drug safety and efficacy profiles. Businesses are also progressively implementing informatics technologies to reduce the lengthy drug research schedule. Curve Therapeutics Ltd., for example, will use the CDD Vault system to manage its biologically coded Microcycle technology in December 2020. It is a widely used hosted platform for applications in medicine, biotechnology, and educational institutions for the secure and frictionless exchange of data in actual time, encouraging cooperative discoveries.

The  acceleration of Covid-19 drug discovery is helping to market growth. For example, scientists used virtual testing using drugs from the DrugBank to target viral proteins and human ACE2 receptors to provide quick answers. This research used silico techniques to identify small compounds that could be used in drug discovery against Covid-19. Similarly, firms are creating various digital services and solutions to aid in the various stages of developing drugs for Covid-19.

For instance, Novartis funded around USD 59 million to spend on underserved illness study and development in 2021, based on the 2021 Annual report, as identified by the Access to Medicine Foundation as research and development areas of greatest need. As an outcome of these expenditures, many formerly fatal diseases are now controllable and even treatable, and this pattern is projected to continue, driving growth. Thus, it is anticipated that demand for Drug Discovery Informatics will increase throughout the projected timeframe due to the rising chronic illness burden. Thus, driving the Drug Discovery Informatics market revenue.

Drug Discovery Informatics Market Segment Insights

Drug Discovery Informatics Product Insights

The  Drug Discovery Informatics market segmentation, based on Product, includes Discovery Informatics and Development Informatics. The discovery informatics segment dominated the market, accounting for 63% of market revenue (USD 1.95 Billion) in 2022, owing to substantial attention on creating precise therapeutics. Precision medicine is tailoring healthcare to a patient's genetic and molecular profile.

Drug Discovery Informatics Mode Insights

The  Drug Discovery Informatics market segmentation, based on Modes, includes In-House Informatics and Outsourced Informatics. The outsourced informatics category generated the highest market revenue of about 51% (USD 1.6 billion) in 2022. Links between pharmaceutical corporations, contractual development, and manufacturing organizations are becoming more common. They develop reports on novel drug entities, which the sponsoring organization or drug manufacturer then utilizes for submission to the US FDA.

Figure 1:  Drug Discovery Informatics Market, by Mode, 2024 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Drug Discovery Informatics Service Insights

The  Drug Discovery Informatics market segmentation, based on Service, includes Sequencing and Target Data Analysis, Docking, Molecular Modeling, Clinical Trial Data Management and Others. The sequencing and target data analysis segment dominated the market, accounting for 43% of market revenue (USD 1.3 Billion) in 2022. Bioinformatic solutions are frequently used to create primary and secondary nucleic acid, protein, and other biomolecule sequencing libraries.

Drug Discovery Informatics Regional Insights

By region, the research provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Drug Discovery Informatics market area will dominate this market during the projected timeframe; this is due to the existence of important market value participants and advanced healthcare infrastructure, as well as the expanding pharmaceutical and biotechnology businesses, as well as the development of next-generation genome sequencing and chemical labs which will boost the market growth in the North American region.

Further, the major countries studied in the market report are the US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2:  Drug Discovery Informatics Market Share by Region 2024 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe region’s Drug Discovery Informatics market accounts for the second-highest market share, attributable to the financial assistance offered by the authorities for developing and researching medications and the increase in therapeutic discovery initiatives. Further, the German Drug Discovery Informatics market holds the largest market share, and the UK Drug Discovery Informatics market is expected to grow and expand significantly in the European region during the projected timeframe.

The Asia-Pacific Drug Discovery Informatics Market is expected to grow quickly during the projected timeframe. This is because of the region's expanding elderly population, rising prevalence of chronic illnesses, increased knowledge, and an increase in the number of clinical trials investigations. Moreover, China’s Drug Discovery Informatics market dominates the market share, and the Indian Drug Discovery Informatics market is expected to expand and grow steadily in the Asia-Pacific region during the projected timeframe.

Drug Discovery Informatics Key Market Players & Competitive Insights

Leading market players invested heavily in research and Development (R&D) to scale up their manufacturing units and develop technologically advanced solutions, which will help the Drug Discovery Informatics market grow worldwide. Market participants are also undertaking various organic or inorganic strategic approaches to strengthen and expand their  footprint, with significant market developments including new product portfolios, contractual deals, mergers and acquisitions, capital expenditure, higher investments, and strategic alliances with other organizations. Businesses are also coming up with marketing strategies such as digital marketing, social media influencing, and content marketing to increase their scope of profit earnings. The Drug Discovery Informatics industry must offer cost-effective and sustainable options to survive in a highly fragmented and dynamic market climate.

Manufacturing locally to minimize operational expenses and offer aftermarket services to customers is one of the critical business strategies organizations use in the  Drug Discovery Informatics industry to benefit customers and capture untapped market share and revenue. The Drug Discovery Informatics industry has recently offered significant advantages to the medicine and healthcare industry. Moreover, more industry participants are utilizing and adopting cutting-edge technology has grown substantially. Major players in the Drug Discovery Informatics market, including Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Certara, L.P., Infosys Limited, Novo Informatics Pvt. Ltd., Collaborative Drug Discovery Inc., Selvita, Charles River Laboratories, Inc., International Business Machines Corporation, Jubilant Life Sciences Ltd., IO Informatics, Inc., GVK Biosciences Private Limited, and Dassault Systèmes are attempting to expand market share and demand by investing in R&D operations to produce sustainable and affordable solutions.

Atomwise creates ML-based discovery algorithms and leverages deep learning and AI-based neural networks to aid in developing novel medications. It forecasts medication prospects for medical companies, entrepreneurs, and research institutes and uses computational drug development to create pharmaceuticals. Atomwise Inc. announced an expanding collection of joint venture firms in December 2020, comprising virus, OrganAi, and A2i Therapeutics, having programs in viral illness, immunology, cancer, clotting illnesses, and neurology.

Fujitsu Ltd. is a company that works in technology for communication and information. Its business segments include technological Solutions, Ubiquitous Options, Gadget Solutions, and Others. The firm was established on June 20, 1935, and is based in Tokyo, Japan. Fujitsu, an ICT supplier, will collaborate with the Japanese research institute Riken on next-generation IT drug discovery technologies to drive a digital shift in drug discovery.

Key organizations in the Drug Discovery Informatics market include

• Thermo Fisher Scientific, Inc.


• PerkinElmer, Inc.


• Certara, L.P.


• Infosys Limited


• Novo Informatics Pvt. Ltd.


• Collaborative Drug Discovery Inc.


• Selvita


• Charles River Laboratories, Inc.


• International Business Machines Corporation


• Jubilant Life Sciences Ltd.


• IO Informatics, Inc.


• GVK Biosciences Private Limited


• Dassault Systèmes

Drug Discovery Informatics Industry Developments

May 2022:Fujitsu, an ICT supplier, will collaborate with the Japanese research institute Riken on next-generation IT drug discovery technologies to drive a digital shift in drug discovery.

May 2022:PostEra, a biotechnology business specializing in machine learning for experimental drug development, and the National Health Institute will partner to produce antiviral treatments in May 2022, with a first USD 68 million investment in National Health Institute financing.

December 2020:Atomwise Inc. announced an expanding collection of joint venture firms in December 2020, comprising virus, OrganAi, and A2i Therapeutics, having programs in viral illness, immunology, cancer, clotting illnesses, and neurology.

Drug Discovery Informatics Market Segmentation

Drug Discovery Informatics Product Outlook

• Discovery Informatics


• Development Informatics

Drug Discovery Informatics Mode Outlook

• In-house Informatics


• Outsourced Informatics

Drug Discovery Informatics Service Outlook

• Sequencing and Target Data Analysis


• Docking


• Molecular Modeling


• Clinical Trial Data Management


• Others

Drug Discovery Informatics Regional Outlook

• 
  
  Middle East
  
  


• 
  
  Africa
  
  


• 
  
  Latin America